Ascendis Pharma (ASND) announced the FDA has accepted for priority review its New Drug Application for TransCon CNP for the treatment of children with achondroplasia and has set a PDUFA goal date of November 30, 2025 to complete its review. The FDA also informed Ascendis that they are not currently planning to hold an advisory committee meeting to discuss this application.
TransCon CNP is an investigational prodrug of C-type natriuretic peptide administered once weekly and designed to treat people living with achondroplasia.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.